MXPA06000691A - Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas. - Google Patents
Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas.Info
- Publication number
- MXPA06000691A MXPA06000691A MXPA06000691A MXPA06000691A MXPA06000691A MX PA06000691 A MXPA06000691 A MX PA06000691A MX PA06000691 A MXPA06000691 A MX PA06000691A MX PA06000691 A MXPA06000691 A MX PA06000691A MX PA06000691 A MXPA06000691 A MX PA06000691A
- Authority
- MX
- Mexico
- Prior art keywords
- antibiotic
- factors
- compositions
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 3
- QWWVBNODQCWBAZ-WHFBIAKZSA-N (2r)-2-amino-3-[(2r)-2-carboxy-2-(methylamino)ethyl]sulfanylpropanoic acid Chemical compound CN[C@H](C(O)=O)CSC[C@H](N)C(O)=O QWWVBNODQCWBAZ-WHFBIAKZSA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 108010062877 Bacteriocins Proteins 0.000 abstract 1
- 241000192125 Firmicutes Species 0.000 abstract 1
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 abstract 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 abstract 1
- 241000906785 Microbispora sp. Species 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960003085 meticillin Drugs 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invencion se relaciona con una sustancia antibiotica de origen microbiano, denominada arbitrariamente como antibiotico 107891 la cual se produce por fermentacion del genero Microbispora ATCC PTA-5024, las sales farmaceuticamente aceptables y composiciones de las mismas y su uso como un agente antibacteriano que tiene actividad inhibidora contra microbios susceptibles; el antibiotico 107891, el cual es un complejo que comprende dos factores, denominados factor A1 y A2 tiene una estructura peptidica que contiene lantionina y metil-lantionina como constituyentes los cuales son tipicos caracteristicos de los antibioticos del grupo de los lantibioticos; el antibiotico 107891 y sus factores A1 y A2 muestran una buena actividad antibacteriana contra bacterias grampositivas que incluyen a cepas resistentes a meticilina y resistentes a vancomicina, y es activa tambien contra algunas bacterias grammnegativas tales como M. catharralis, la especie Neisseria y H. influenzae y Mycobacteria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03016306 | 2003-07-18 | ||
| PCT/EP2004/007658 WO2005014628A1 (en) | 2003-07-18 | 2004-07-12 | Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06000691A true MXPA06000691A (es) | 2006-04-11 |
Family
ID=34130026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06000691A MXPA06000691A (es) | 2003-07-18 | 2004-07-12 | Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7307057B2 (es) |
| EP (1) | EP1646646B1 (es) |
| JP (1) | JP4163737B2 (es) |
| AR (1) | AR046809A1 (es) |
| AT (1) | ATE356143T1 (es) |
| BR (1) | BRPI0412591A (es) |
| CA (1) | CA2529124C (es) |
| DE (1) | DE602004005203T2 (es) |
| ES (1) | ES2281808T3 (es) |
| MX (1) | MXPA06000691A (es) |
| TW (1) | TWI340167B (es) |
| WO (1) | WO2005014628A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7351687B2 (en) * | 2003-07-18 | 2008-04-01 | Vicuron Pharmaceuticals, Inc. | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
| US7319088B2 (en) | 2003-07-18 | 2008-01-15 | Vicuron Pharmaceuticals Inc. | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
| WO2006075988A1 (en) | 2005-01-12 | 2006-07-20 | Vicuron Pharmaceuticals Inc. | Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof |
| PL1855705T3 (pl) * | 2005-01-12 | 2012-12-31 | Sentinella Pharmaceuticals Inc Sentinella | Antybiotyk 107891, jego czynniki, farmaceutycznie dopuszczalne sole i kompozycje oraz ich zastosowanie |
| GB0600928D0 (en) | 2006-01-17 | 2006-02-22 | Novacta Biosystems Ltd | Improvements relating to lantibiotics |
| GB0714030D0 (en) * | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | The use of type-B lantibiotic-based compounds having antimicrobial activity |
| GB0714029D0 (en) | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | Lantibiotic-based compounds having antimicrobial activity |
| WO2009019524A1 (en) | 2007-08-03 | 2009-02-12 | Naicons S.C.A.R.L. | Genes and proteins for the biosynthesis of the lantibiotic 107891 |
| RS53586B1 (sr) | 2009-01-14 | 2015-02-27 | Novacta Biosystems Limited | Derivati deoksiaktagardina |
| KR20110122139A (ko) | 2009-02-04 | 2011-11-09 | 노박타 바이오시스템스 리미티드 | 액타가르딘 유도체 |
| GB201001688D0 (en) | 2010-02-02 | 2010-03-17 | Novacta Biosystems Ltd | Compounds |
| GB201013513D0 (en) | 2010-08-11 | 2010-09-22 | Novacta Biosystems Ltd | Formulations |
| US9975930B2 (en) | 2012-11-30 | 2018-05-22 | Naicons S.R.L. | Lantibiotic derivatives and process for their preparation |
| US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
| MX2020000265A (es) | 2017-07-07 | 2020-07-22 | Epicentrx Inc | Composiciones para la administración parenteral de agentes terapéuticos. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59198982A (ja) * | 1983-04-28 | 1984-11-10 | Meiji Seika Kaisha Ltd | 新抗生物質ｓｆ−２２４０物質およびその製造法 |
| EP0592835A3 (en) * | 1992-09-23 | 1995-03-15 | Bristol Myers Squibb Co | BU-4803T antibiotics. |
| US6551591B1 (en) | 2001-09-07 | 2003-04-22 | Essential Therapeutics, Inc. | Antibiotics from microbispora |
-
2004
- 2004-07-12 AT AT04740916T patent/ATE356143T1/de not_active IP Right Cessation
- 2004-07-12 BR BRPI0412591-6A patent/BRPI0412591A/pt not_active IP Right Cessation
- 2004-07-12 DE DE602004005203T patent/DE602004005203T2/de not_active Expired - Lifetime
- 2004-07-12 JP JP2006520724A patent/JP4163737B2/ja not_active Expired - Fee Related
- 2004-07-12 ES ES04740916T patent/ES2281808T3/es not_active Expired - Lifetime
- 2004-07-12 EP EP04740916A patent/EP1646646B1/en not_active Expired - Lifetime
- 2004-07-12 CA CA2529124A patent/CA2529124C/en not_active Expired - Fee Related
- 2004-07-12 WO PCT/EP2004/007658 patent/WO2005014628A1/en not_active Ceased
- 2004-07-12 US US10/521,336 patent/US7307057B2/en not_active Expired - Lifetime
- 2004-07-12 MX MXPA06000691A patent/MXPA06000691A/es active IP Right Grant
- 2004-07-15 TW TW093121124A patent/TWI340167B/zh not_active IP Right Cessation
- 2004-07-19 AR ARP040102548A patent/AR046809A1/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AR046809A1 (es) | 2005-12-28 |
| US20060183673A1 (en) | 2006-08-17 |
| EP1646646B1 (en) | 2007-03-07 |
| ES2281808T3 (es) | 2007-10-01 |
| TW200510541A (en) | 2005-03-16 |
| US7307057B2 (en) | 2007-12-11 |
| ATE356143T1 (de) | 2007-03-15 |
| JP2007525479A (ja) | 2007-09-06 |
| DE602004005203T2 (de) | 2007-11-22 |
| DE602004005203D1 (de) | 2007-04-19 |
| TWI340167B (en) | 2011-04-11 |
| CA2529124C (en) | 2011-02-08 |
| JP4163737B2 (ja) | 2008-10-08 |
| WO2005014628A1 (en) | 2005-02-17 |
| BRPI0412591A (pt) | 2006-09-19 |
| EP1646646A1 (en) | 2006-04-19 |
| CA2529124A1 (en) | 2005-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Giacometti et al. | In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics | |
| Giamarellou et al. | In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa | |
| MXPA06000691A (es) | Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas. | |
| WO2006065977A3 (en) | Antimicrobial peptides and methods of use | |
| CY1113030T1 (el) | Αντιβιοτικο 107891, παραγοντες του, φαρμακευτικως αποδεκτα αλατα και συνθεσεις και η χρηση τους | |
| Fan et al. | Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria | |
| JP2012513467A5 (es) | ||
| GB0026924D0 (en) | Antibacterial agents | |
| EP4289480A3 (en) | Macrocyclic broad spectrum antibiotics | |
| GB8507528D0 (en) | Basis monocarboxyamide derivatives | |
| Williams et al. | Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp. | |
| UA87546C2 (ru) | Антибиотик 107891, его факторы а1 и а2, фармацевтически приемлемые соли, композиция и их использование | |
| KR101970656B1 (ko) | 신규한 스트렙토마이시스 리노마이시니 ds620 균주 및 이의 추출물을 포함하는 항균 조성물 | |
| TNSN07262A1 (fr) | Antibiotique 107891, ses facteurs a1 et a2, ses sels pharmaceutiquement acceptables et des compositions en contenant, et leurs utilisations | |
| Jorgensen et al. | Antibacterial activity of the new glycopeptide antibiotic SKF104662 | |
| Maskell et al. | Comparative inhibitory and bactericidal activities of FCE 22101 against Gram-positive cocci and anaerobes in vitro | |
| Marshall et al. | Spectrum and antimicrobial activity of alexomycin (PNU-82, 127), a peptide compound projected for use in animal health | |
| WO2025186334A8 (en) | Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity | |
| IL161896A0 (en) | Antibiotics ge 81112 factors a, b, b1 pharmaceutically acceptable salts and compositions, and use thereof | |
| Anderegg et al. | Multicenter Quality Control Evaluation Results for Dalbavancin (BI397), An Investigational Glycopeptide With Potent Gram-Positive Activity | |
| Chosy | Combatting Bacterial Pathogens: Design, Evaluation, and Introduction of Novel Guanidinium-Rich Antibiotic Conjugates | |
| Arooj et al. | Texiobactin, a Potent Killer of Antibiotic Resistant Pathogens | |
| Morrissey et al. | The activity of LTX-109 against a range of recent gram positive and gram negative clinical isolates | |
| Fremaux et al. | In vitro activity of cefpirome against Streptococcus pneumoniae strains with decreased susceptibility to cefotaxime | |
| MY149603A (en) | Novel antibiotics, bispolides a1, a2, and a3, as well as bispolides b1, b2a, b2b and b3, and process for producing these antibiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights | ||
| GB | Transfer or rights |